Arrowhead Pharmaceuticals (NASDAQ:ARWR) Now Covered by Analysts at Stifel Nicolaus

Stifel Nicolaus started coverage on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) in a research report released on Tuesday, MarketBeat Ratings reports. The brokerage issued a buy rating and a $98.00 price target on the biotechnology company’s stock.

A number of other brokerages have also recently issued reports on ARWR. HC Wainwright reissued a “buy” rating and issued a $100.00 target price on shares of Arrowhead Pharmaceuticals in a report on Wednesday, July 1st. Chardan Capital reiterated a “buy” rating and issued a $90.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, June 30th. Leerink Partners upped their price target on Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the company a “market perform” rating in a research report on Wednesday, June 17th. Royal Bank Of Canada lifted their price objective on Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the company an “outperform” rating in a report on Friday, May 8th. Finally, Weiss Ratings lowered shares of Arrowhead Pharmaceuticals from a “hold (c-)” rating to a “sell (d-)” rating in a report on Wednesday, May 20th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Arrowhead Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $88.17.

Arrowhead Pharmaceuticals Stock Performance

NASDAQ ARWR opened at $71.91 on Tuesday. Arrowhead Pharmaceuticals has a twelve month low of $14.30 and a twelve month high of $87.83. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 1.41. The stock has a market cap of $10.13 billion, a P/E ratio of -33.45 and a beta of 1.26. The company’s 50-day simple moving average is $77.86 and its 200 day simple moving average is $69.43.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.93) EPS for the quarter, topping analysts’ consensus estimates of ($1.10) by $0.17. The firm had revenue of $73.74 million during the quarter, compared to analysts’ expectations of $73.84 million. Arrowhead Pharmaceuticals had a negative net margin of 48.38% and a negative return on equity of 55.09%. The company’s revenue for the quarter was down 86.4% compared to the same quarter last year. During the same quarter last year, the company earned $2.75 earnings per share. As a group, research analysts forecast that Arrowhead Pharmaceuticals will post -3 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Daniel Joseph Apel sold 13,095 shares of the company’s stock in a transaction that occurred on Wednesday, April 22nd. The shares were sold at an average price of $71.35, for a total transaction of $934,328.25. Following the transaction, the chief financial officer directly owned 162,905 shares in the company, valued at approximately $11,623,271.75. This represents a 7.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider James C. Hamilton sold 10,000 shares of the stock in a transaction that occurred on Thursday, April 23rd. The shares were sold at an average price of $75.00, for a total transaction of $750,000.00. Following the sale, the insider directly owned 226,958 shares in the company, valued at $17,021,850. This trade represents a 4.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 26,065 shares of company stock valued at $1,912,662. Insiders own 3.60% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Tsfg LLC bought a new position in Arrowhead Pharmaceuticals in the 4th quarter valued at $25,000. Optiver Holding B.V. raised its position in shares of Arrowhead Pharmaceuticals by 83.8% during the first quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock worth $26,000 after acquiring an additional 186 shares during the last quarter. Versant Capital Management Inc raised its position in shares of Arrowhead Pharmaceuticals by 285.1% during the second quarter. Versant Capital Management Inc now owns 335 shares of the biotechnology company’s stock worth $27,000 after acquiring an additional 248 shares during the last quarter. Carolina Wealth Advisors LLC lifted its stake in shares of Arrowhead Pharmaceuticals by 80.6% during the second quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 154 shares during the period. Finally, iSAM Funds UK Ltd acquired a new position in shares of Arrowhead Pharmaceuticals during the third quarter valued at $29,000. Institutional investors own 62.61% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.